Jennison Associates
BDTX icon

Jennison Associates’s Black Diamond Therapeutics BDTX Stock Holding History

Jennison Associates’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-364,416
Closed -$11.7M – 669
2020
Q4 		$11.7M Sell
364,416
-3,949
-1% -$130K 0.01% 392
2020
Q3 		$11.1M Sell
368,365
-60,441
-14% -$1.84M 0.01% 369
2020
Q2 		$18.1M Buy
428,806
+2,268
+0.5% +$83.5K 0.02% 309
2020
Q1 		$10.6M Buy
+426,538
New +$13M 0.01% 326

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Jennison Associates's BDTX Position: Q1 2021 in Review

Jennison Associates sold out of Black Diamond Therapeutics (BDTX) in Q1 2021, closing a stake of 364,416 shares — an estimated $11.7M sold.

Jennison Associates first reported a position in BDTX in Q1 2020 and held it in 4 quarters. The position peaked at $18.1M in Q2 2020. 113 funds tracked by Wall St. Rank hold BDTX as of Q1 2021.

  • Jennison Associates reported no remaining Black Diamond Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Jennison Associates sold 364,416 Black Diamond Therapeutics shares in Q1 2021, an estimated $11.7M.
  • Jennison Associates first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 4 quarters.
  • Jennison Associates's Black Diamond Therapeutics position peaked at $18.1M in Q2 2020.
  • 113 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2021.

Based on Jennison Associates's 13F filing for Q1 2021, filed 11 May 2021.